The efficacy of cue exposure therapy on treatment outcome of stimulant use disorder

Not Applicable

Recruiting

Conditions: stimulant use disorder.
Other stimulant dependence

Registration Number: IRCT20180218038782N1

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Male

Target Recruitment: 40

Inclusion Criteria

stimulant use disorder diagnosis
not using any kind of drug except of nicotine within two weeks before program starting
Ability of reading and writing persian language
Completion of informed consent form

Exclusion Criteria

having sever suicidal ideation
having psychotic symptoms
having acute physical problems

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment outcome includes: addiction severity, craving, relapse rate, quality of life and severity of depression, anxiety and stress that will be measured by addiction severity index (ASI), Desires for Drug Questionnaire (DDQ), Obsessive Compulsive Drug Use Scale (OCDUS), urine test, World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Depression Anxiety Stress Scales (DASS-21). Timepoint: assessment will complete at pre-test, post-test and follow up (3 months after treatment completion). Method of measurement: addiction severity index (ASI), Desires for Drug Questionnaire (DDQ), Obsessive Compulsive Drug Use Scale (OCDUS), urine test, World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Depression Anxiety Stress Scales (DASS-21).

Secondary Outcome Measures

Name	Time	Method
Addiction severity. Timepoint: pretest, post test, 3 months follow up. Method of measurement: addiction severity index (ASI).;Craving. Timepoint: pretest, post test, 3 months follow up. Method of measurement: Desires for Drug Questionnaire (DDQ) and Obsessive Compulsive Drug Use Scale (OCDUS).;Relapse rate. Timepoint: pretest, post test, 3 months follow up. Method of measurement: urine test.;Quality of life. Timepoint: pretest, post test, 3 months follow up. Method of measurement: World Health Organization Quality of Life-Brief (WHOQOL-BREF).;Severity of depression, anxiety and stress. Timepoint: pretest, post test, 3 months follow up. Method of measurement: Depression Anxiety Stress Scales (DASS-21).